Spots Global Cancer Trial Database for A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
Official Title: A Phase 1 Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies
Study ID: NCT03329950
Conditions
Study Description
Brief Summary: This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
Detailed Description: This study will determine the MTD of CDX-1140 while also evaluating the safety, tolerability and efficacy of CDX-1140 alone (Part 1) or in combination with CDX-301 (Part 2), pembrolizumab (Part 3), or chemotherapy (Part 4) in patients with cancer. Eligible patients that enroll to the dose-escalation portion of the study will be assigned to one of several dose levels of CDX-1140. The dose-escalation part of the study will test the safety profile of CDX-1140, alone or in combination with CDX-301, pembrolizumab or chemotherapy and determine which dose(s) of CDX-1140 will be studied in the expansion portions of the study. All patients enrolled in the study will be closely monitored to determine if there is a response to the treatment as well as for any side effects that may occur.
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
HonorHealth Research Insititute, Scottsdale, Arizona, United States
Northside Hospital, Inc., Atlanta, Georgia, United States
Georgia Cancer Center at Augusta University, Augusta, Georgia, United States
Oncology Hematology West, PC dba Nebraska Cancer Specialists, Omaha, Nebraska, United States
Icahn School of Medicine at Mount Sinai, New York, New York, United States
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Gabrail Cancer Center Research LLC, Canton, Ohio, United States
Providence Portland Medical Center, Portland, Oregon, United States
Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Rhode Island Hospital (RIH) The Miriam Hospital (TMH), Providence, Rhode Island, United States
Houston Methodist, Houston, Texas, United States
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
